Medical University of Vienna, Vienna, Austria.
Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel.
Cardiovasc Diabetol. 2019 Aug 31;18(1):115. doi: 10.1186/s12933-019-0920-3.
EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.
EMPA-REG OUTCOME 被国际指南公认为一项具有里程碑意义的研究，该研究表明恩格列净可显著降低 2 型糖尿病（T2D）合并心血管疾病患者的心血管风险。为评估恩格列净在常规临床实践中的影响，正在进行的 EMPRISE 研究正在收集真实世界证据，以比较恩格列净与 DPP-4 抑制剂在有效性、安全性和卫生经济学结局方面的差异。最近发表了 EMPRISE 的一项计划中的中期分析结果，证实了在不同患者人群中，恩格列净可显著降低心力衰竭住院率。在这篇评论文章中，我们将结合当前的证据和临床指南，讨论新数据，同时也站在具有 T2D 患者心血管风险管理经验的临床医生的角度来分析。我们还展望了 EMPRISE 可能提供的未来研究结果，随着未来几年证据的积累，将进一步补充 EMPA-REG OUTCOME 的重要发现。
